Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2025)

Historic Change in Receivables for BridgeBio Pharma (BBIO) over the last 2 years, with Q3 2025 value amounting to $39.6 million.

  • BridgeBio Pharma's Change in Receivables rose 2188571.43% to $39.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.0 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2024, which is 11938.28% up from last year.
  • BridgeBio Pharma's Change in Receivables amounted to $39.6 million in Q3 2025, which was up 2188571.43% from -$38.4 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Change in Receivables ranged from a high of $233.7 million in Q1 2024 and a low of -$234.8 million during Q2 2024